H&R Block to Participate in the JP Morgan 2023 Equity Opportunities Forum
October 23, 2023 16:35 ET | HRB Tax Group, Inc.
KANSAS CITY, Mo., Oct. 23, 2023 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) today announced that Tony Bowen, Chief Financial Officer, and Michaella Gallina, Vice President, Investor...
Mordor Intelligence Logo_Comp.png
Brazil Retail Banking Market Revenues to Reach USD 212.83 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 16, 2023 09:30 ET | Mordor Intelligence
Hyderabad, Aug. 16, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Brazil Retail Banking Market Report (2023-2028)," the market is estimated at USD 128.02 billion in...
CSX Chief Financial Officer to Address JP Morgan Industrials Conference
March 08, 2023 10:00 ET | CSX Corporation
JACKSONVILLE, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) Executive Vice President and Chief Financial Officer, Sean Pelkey, will address the 2023 JP Morgan Industrials...
Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco
January 09, 2023 08:30 ET | Blue Water Vaccines Inc.
CINCINNATI, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
InnovAge Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 08:00 ET | InnovAge
DENVER, Jan. 05, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), a market leading healthcare delivery platform for high-cost, dual-eligible seniors,...
InflaRx on large white.jpg
InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
January 05, 2023 07:30 ET | InflaRx N.V.
Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient...
Dyadic Logo Current.jpg
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Leon_Logo for GNW.jpg
LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
January 03, 2023 09:00 ET | leon-nanodrugs GmbH
LEON achieved superior accuracy in development of its proprietary reactor, facilitating exceptional inter-device reproducibility of particle size and distribution, and thus seamless process transfer,...
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:00 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Abel Noser
Abel Noser Finishes Year with an Impressive List of Achievements
December 29, 2022 06:30 ET | Abel Noser
New York, NY, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Abel Noser Holdings, the market leader in institutional trade analytics and agency-only trading solutions, has many notable achievements to look back...